The only reason this stock isn't lower has to do wit the cash on hand. Reality is the halted trial is a huge blow and could mean the end for their platform. Everyone talking about how the FDA will resume the trial in the next month is smoking dope.
Even the CEO moved everything out to 2018 for approval which is a full year. When you have 3 deaths your new submission to continue the trial better be air tight. This isn't okay we are going to back off the dosage or inclusion of another compound and everything will be fine.
I do think this treatment has promise, but when you mess with mother nature there is a lot of risk and its surely not black and white. I hope for cancer patients they come up with a better treatment because Chemo and radiation are so barbaric.
There are other approaches, but many just don't get the time of day because it interferes with the big dollars the BP's have captured and won't give up. This entire biotech start up and new platform game has a lot of potential, but its real hard to get any traction.
Celgene pumping $1B into it was huge and explained why JUNO was able to gain a much larger market cap, but a billion (what it use to take for a drug to get to market) isn't what it use to be and now it takes $10B to get a new drug to market. Dead money for the time being with major risk. A new start of the trial should pop this stock, but people thinking that's a given are fooling themselves.
